Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Biocon Receives European Commission Approval for Breast Cancer Biosimilar Pebrilzo

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Biocon Receives European Commission Approval for Breast Cancer Biosimilar Pebrilzo

Analysed 18 Nov 2026·2 sources analysed·India·Business
Biocon Receives European Commission Approval for Breast Cancer Biosimilar PebrilzoPreviousNext

Biocon Limited has received marketing authorisation from the European Commission for Pebrilzo, its pertuzumab biosimilar, to treat HER2-positive breast cancer across various stages in the EU. This approval follows a positive opinion from the European Medicines Agency and recent US FDA approval. Pebrilzo is the first biosimilar approved under the EMA's new tailored clinical approach and is indicated for use with trastuzumab and chemotherapy in early, locally advanced, inflammatory, and metastatic breast cancer cases.

Sentiment
69%
TBN's observations

First-hand measurement across 2 sources

We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (69/100). Lens Score 46/100.

Outlets measured: mint, businessstandard. See how each one headlined and framed the same story in the source comparison below.

AI analysis of 2 sources · Published under editorial oversight by The Balanced News
Analysed 18 Nov 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Sentiment — Positive (69/100)

Sentiment was consistent across outlets (68–70/100), indicating broadly factual reporting rather than editorialising.

Coverage timeline

businessstandard broke this story on 18 Nov, 03:55 am. Other outlets followed.

18 Nov, 03:55 am2 sources · 45 min18 Nov, 04:40 am
  1. 1
AI analysis by the TBN Bias Engine · beat methodology byMrunal Wange· Business & Economy Editor· editorial standards byOjas Kale
← Previous
Motilal Oswal Reiterates Buy on Poonawalla Fincorp with INR 600 Target
Next →
Sony Wins UK Lawsuit Over PlayStation Store Pricing Allegations
businessstandard18 Nov, 03:55 am
Biocon's Pebrilzo gets EU nod for HER2-positive breast cancer treatment
  • 2
    mint18 Nov, 04:40 am
    Biocon gets European Commission nod for breast cancer biosimilar Pebrilzo
  • Who's involved

    Institutions and figures named across source coverage.

    Government
    United States Food and Drug AdministrationEuropean CommissionEuropean Medicines AgencyCommittee for Medicinal Products for Human Use
    Corporate
    Biocon Limited

    Story context

    Category
    Business
    Location
    India
    Sources analysed
    2
    Last analysed
    18 Nov 2026
    Key entities
    HER2PertuzumabBioconBiosimilarEuropean CommissionEuropean UnionCommittee for Medicinal Products for Human UseFood and Drug AdministrationEuropean Medicines AgencyTrastuzumabIntravenous therapyMetastasis